Evidence map›Paper›PMID 26942082›Full record

ArticleOncoimmunology

SA-4-1BBL/MPL as a novel immune adjuvant platform to combat cancer.

Abhishek K Srivastava, Esma S Yolcu, Gunes Dinc, Rajesh K Sharma, Haval Shirwan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. A Unique Combination of MnThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abhishek K SrivastavaInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD USA.
Esma S YolcuInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA.
Gunes DincInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; Present affiliation: Ahi Evran University, School of Medicine, Department of Medical Biyology, Kirsehir, Turkey.
Rajesh K SharmaInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville , Louisville, KY, USA.
Haval ShirwanInstitute for Cellular Therapeutics, Department of Microbiology and Immunology, University of Louisville, Louisville, KY, USA; James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Practical experience with cancer vaccines combined with accumulated knowledge of the complex interactions between cancer and immune system rationalize the combinatorial use of immune adjuvants for better efficacy. We recently described a novel adjuvant system based on the costimulatory SA-4-1BBL and TLR4 agonist MPL that has desired therapeutic and safety profiles.

Indexed as

Adjuvant systemscancer vaccinesCD137lung cancerMPLSA-4-1BBLTLR

Identifiers

PMID26942082
PMCPMC4760279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.